Antimicrobial resistance is on the rise. Neisseria gonorrhea (NG) — also known as Gonococcus (GC) — already developed resistance to multiple classes of antibiotics and is classified as “urgent threat” by the Centers for Disease Control and Prevention.1 Today, advances in testing can enable more accurate treatment, and aims to help healthcare professionals preserve last-line antibiotics for future use.
Through a partnership with SpeeDx, a developer of innovative molecular diagnostic solutions, Roche is ushering in a new era of resistance-focused diagnostics.
ResistancePlus® GC, powered by proprietary PlexPCR® technology, is a multiplex qPCR test used to detect NG and sequences linked to ciprofloxacin susceptibility. Informing treatment pathways with ResistancePlus® GC can ensure the most appropriate antimicrobial is used for front-line therapy, protecting patients and their partners.
Reflex testing (with resistance profiling) for all non-empirically treated patients, enables more targeted treatment to support the optimal outcome.
Leveraging the flexible PlexPrime® design allows for increased specificity and reduced competition while distinctly different amplicons aid in allele-specific detection in multiplexed format.
ResistancePlus® GC is a multiplex qPCR test for detection of Neisseria gonorrhoeae and mutations linked with susceptibility or resistance to ciprofloxacin, validated for a range of specimen types.
Simultaneously detect NG and wild-type/mutant sequences as markers
of susceptibility to ciprofloxacin.
Reduce instances of false positives from cross reaction with other non-gonococcal Neisseria species found in the pharynx.
Easy adoption: Fits into any laboratory workflow, providing both detection as well as ciprofloxacin susceptibility in a single test
Improved patient pathway: Delivers rapid resistance data, reducing the need for injectable antibiotics while freeing-up clinical staff
Antimicrobial stewardship: Informs a patient’s treatment pathway, ensuring the most appropriate antimicrobial is used for front-line therapy
Testing compliance: Meets current and emerging International, European and Australian guideline recommendations
Platform compatibility: Validated to work on a number of extraction platforms, with amplification/detection on the LightCycler® 480 Instrument II and the cobas z 480 Analyzer
PlexZyme® technology offers high performance and reliable qPCR detection.
During PlexPCR®, primers amplify target nucleic acid sequences and produce amplicons, which serve as a template for PlexZyme® formation. Once the partzymes have assembled into PlexZyme® enzymes, universal probes bind and enzymatic cleavage of the probes between fluorophore and quencher dye pairs generates fluorescence. Changes in fluorescence allow detection and/or quantification of the target nucleic acid in real time.
PlexPrime® is a novel method for nucleic acid amplification that creates amplicons, which are distinctly different from the parent sequence. The combination of PlexPrime® and PlexPrime® technology enables multiplex mutation detection with high sensitivity and specificity.3
The ResistancePlus® GC kit is a qualitative real-time PCR assay for the detection of Neisseria gonorrhoeae and the gyrA S91 wild-type and S91F mutant markers that are associated with susceptibility or resistance to ciprofloxacin. The ResistancePlus® GC kit can be used with the specimen types listed in the Instructions for Use (IFU).
Registration status: CE-IVD, not yet available in the U.S.
ResistancePlus® GC kits are developed and manufactured by SpeeDx Pty Ltd, Sydney and distributed by Roche.
LIGHTCYCLER® and COBAS Z are trademarks of Roche.
PlexPCR®, PlexZyme®, PlexPrime®, and ResistancePlus® are trademarks of SpeeDx Pty Ltd.